Development and characterization of catechin-in-cyclodextrin-in-phospholipid liposome to eradicate MRSA-mediated surgical site infection: Investigation of their anti-infective efficacy through in vitro and in vivo studies

Methicillin-resistant Staphylococcus aureus (MRSA) is one of the prime pathogens responsible for surgical site infection (SSI). Treatment of SSI remains challenging because of resistant nature of MRSA, which is a major threat in recent years. Our previous work revealed the antibacterial potential of catechin isolated from cashewnut shell against MRSA. However, the application of catechin to treat MRSA-mediated SSI is hampered because of its poor solubility and low trans-dermal delivery. Hence, the present study focused on developing catechin-in-cyclodextrin-in-phospholipid liposome (CCPL) and evaluating its physicochemical characteristics and anti-infective efficacy through in vitro and in vivo models. Encapsulation of catechin with beta-cyclodextrin and soybean lecithin was confirmed through UV-Vis spectroscopy, FTIR, and XRD techniques, while TEM imaging revealed the size of CCPL (206 nm). The CCPL displayed a higher level of water solubility (25.13%) and in vitro permeability (42.14%) compared to pure catechin. A higher level of encapsulation efficiency (98.9%) and antibacterial activity (19.8 mm of ZOI and 31.25 mu g/mL of MIC) were noted in CCPL compared to the catechin/ cyclodextrin complex. CCPL recorded significant and dose-dependent healing of the incision, significant reduction of bacterial count, improved epithelization, and effective prevention of inflammation in skin samples of SSI-induced Balb/c mice. Data of the present work suggest that the CCPL could be considered as a novel and potential candidate to mitigate MRSA-mediated SSI after clinical trials.

Automated summary

The study developed catechin-in-cyclodextrin-in-phospholipid liposome (CCPL) as a potential novel drug for treating MRSA-mediated surgical site infection (SSI). CCPL demonstrated higher water solubility and in vitro permeability, significant antibacterial activity, and healing effects. Therefore, CCPL may be considered a promising candidate for treating MRSA-induced SSI after clinical trials.